Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: October 6, 2022

Patent: 4,737,462

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 4,737,462
Title: Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-.beta.
Abstract:A modified IFN-.beta. is provided wherein the cysteine residue at position 17 is deleted and serine is substituted therefor. DNA sequences coding for the modified protein, nucleotide primers used for the mutagenesis, appropriate cloning vectors, host organisms transformed with the vectors, methods for the production and use of the modified IFN-.beta. (IFN-.beta..sub.ser17) are also provided. The specific activity of IFN-.beta..sub.ser17 is found to be substantially the same as that of native IFN-.beta..
Inventor(s): Mark; David F. (Hercules, CA), Lin; Leo S. (Fremont, CA), Yu Lu; Shi-Da (Oakland, CA)
Assignee: Cetus Corporation (Emeryville, CA)
Application Number:06/753,717
Patent Claims:see list of patent claims

Details for Patent 4,737,462

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bayer Healthcare Pharmaceuticals Inc. BETASERON interferon beta-1b For Injection 103471 07/23/1993 See Plans and Pricing 2005-04-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 4,737,462

Country Patent Number Estimated Expiration
South Africa 837789 See Plans and Pricing
United States of America RE33653 See Plans and Pricing
United States of America 4853332 See Plans and Pricing
United States of America 4588585 See Plans and Pricing
United States of America 4518584 See Plans and Pricing
Portugal 77512 See Plans and Pricing
Philippines 23702 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.